Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 4, 2000, Pages 486-491

  Cronin, Eugenia K ^a   Normand, Charles ^a   Henthorn, Joan S ^b   Graham, Vesna ^b   Davies, Sally C ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN VARIANT;

ARTICLE; BETA THALASSEMIA; COST EFFECTIVENESS ANALYSIS; COUNSELING; DEVICE; FEMALE; FETUS; FETUS DISEASE; FOLLOW UP; GENETIC SCREENING; HEALTH CARE COST; HEMOGLOBINOPATHY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MATERNAL DISEASE; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SICKLE CELL ANEMIA; THALASSEMIA; UNITED KINGDOM;

ALGORITHMS; COMMUNITY HEALTH PLANNING; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; FEMALE; FETAL DISEASES; HEMOGLOBINOPATHIES; HUMANS; LONDON; PREGNANCY; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES;

EID: 0034017940     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb13267.x     Document Type: Article

References (10)

1. Working Party of the Standing Medical Advisory Committee on Sickle Cell, Thalassaernia and other Haemoglobinopathies, Report, London: HMSO, 1993.
2. Bassett P, Beuzard Y, Garel MC, Rosa J. Isoelectric focusing in human haemoglobins: its application to screening, to characterization of 70 variants and to study of modified fractions of normal haemoglobins. Blood 1978; 51: 971–982.
3. Johnson CS, Moyes D, Schroeder WA, Shelton JR, Beutler E. Hemoglobin Pasadena alpha 2 beta (E 19) leads to Arg. Identification by high performance liquid chromatography of a new unstable variant with increased oxygen affinity. Biochimica et Biophysica Acta 1980; 623: 360–367.
4. Thalassaemia Working Party of the BCSH General Haematology Task Force, Guidelines for investigation of the α and β thalassaemia traits. J Clin Pathol 1994; 47: 4, 289–295.
5. Huntsman RG, Barclay GPT, Canning DM, Yawson GI. A rapid whole blood solubility test to differentiate the sickle cell trait from sickle cell anaemia. J Clin Pathol 1970; 23: 781–783.
6. Brozovic M, Henthorn J. Investigation of abnormal haemoglobins and thalassaemia. In: Dacie JV, Lewis SM, editors. Practical Haematology, 8th edition. London: Churchill Livingstone, 1995.
7. Modell B, Anionwu EN. Guidelines for screening for haemoglobin disorders: services specifications for low and high prevalence DHAs. In: Ethnicity and Health: Reviews of Literature and Guidance for Purchasers in the Areas of Cardiovascular Disease, Mental Health and Haemoglobinopathies. York: University of York, NHS Centre for Reviews and Dissemination CRD Report 5, Part 4 127–224, 1996.
8. Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease—life expectancy and risk factors for early death. N Eng J Med 1994; 330: 1639–1643.
9. Hickman M, Model B, Greengross Pet et al. Mapping the prevalence of sickle cell and β Thalassaemia in England: estimating and validating ethnic-specific rates. Br J Haematol 1999; 104: 860–867.
10. Greengross P, Hickman M, Gill M, Dugan B, Davies SC. Outcomes of universal antenatal screening for haemoglobinopathies. J Med Screen 1998; 6: 3–10.